Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations

v3.23.1
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue    
Product revenue, net $ 12,165 $ 20,796
Collaboration revenue 181 577
Revenue - related party 35 52
Other revenue 48 2,500
Net revenue 12,429 23,925
Operating expenses    
Cost of goods sold - product revenue 6,449 8,203
Research and development 35,276 36,722
Research and development - licenses acquired 4,230  
Selling, general and administrative 25,341 26,270
Total operating expenses 71,296 71,195
Loss from operations (58,867) (47,270)
Other income (expense)    
Interest income 1,036 142
Interest expense and financing fee (4,296) (2,350)
Foreign exchange loss (47)  
Change in fair value of warrant liabilities 6,678  
Grant income 351  
Total other income (expense) 3,722 (2,208)
Net loss (55,145) (49,478)
Net loss attributable to non-controlling interests 33,608 33,718
Net loss attributable to common stockholders $ (21,537) $ (15,760)
Net loss per common share attributable to common stockholders - basic $ (0.21) $ (0.18)
Net loss per common share attributable to common stockholders - diluted $ (0.21) $ (0.18)
Weighted average common shares outstanding - basic 101,885,648 86,255,142
Weighted average common shares outstanding - diluted 101,885,648 86,255,142